New injectable HIV combo trial pulled before it began
NCT ID NCT06657885
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This was a planned phase 2 study to test a combination of two long-acting drugs, cabotegravir and lenacapavir, for people with HIV who have tried many treatments. The goal was to see if switching to these injections every two months could keep the virus under control. However, the study was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabotegravir and lenacapavir (injectable and oral forms)
What this could lead to
If successful, this could offer a new long-acting injectable option for HIV patients who have difficulty with daily pills or have drug resistance.
What could go wrong
The trial was withdrawn before any participants were enrolled, so no data was collected. The combination is still experimental and may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV1 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de nantes- Hotel Dieu
Nantes, France
-
Centre hospitalier François Mitterrand
Dijon, France
-
Centre hospitalier de Tourcoing
Tourcoing, France
-
Chu- Nice Archet
Nice, France
-
Hopital Bichat Claude Bernard
Paris, 75018, France
-
Hopital Necker
Paris, 75015, France
-
Hopital Pitié Salpêtrière
Paris, 75013, France
-
Hopital Saint André
Bordeaux, France
-
Hopital Saint Antoine
Paris, 75012, France
-
Hopital raymond Poincaré
Garches, France
-
Hopiytal Pellegrin
Bordeaux, France
-
Hôpital Franco-Britannique
Levallois-Perret, France